Compare LINC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | NVAX |
|---|---|---|
| Founded | 1946 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2005 | 1996 |
| Metric | LINC | NVAX |
|---|---|---|
| Price | $40.59 | $7.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $45.00 | $11.33 |
| AVG Volume (30 Days) | 643.0K | ★ 3.6M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 309.76 |
| EPS | ★ 0.14 | N/A |
| Revenue | $261,853,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | $294.43 | ★ N/A |
| Revenue Growth | 32.98 | ★ 64.69 |
| 52 Week Low | $17.29 | $6.20 |
| 52 Week High | $56.34 | $11.85 |
| Indicator | LINC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.44 | 30.13 |
| Support Level | $38.92 | $6.38 |
| Resistance Level | $42.69 | $10.10 |
| Average True Range (ATR) | 2.86 | 0.37 |
| MACD | -1.36 | -0.14 |
| Stochastic Oscillator | 12.25 | 2.03 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.